Researchers recommend monitoring adenovirus mutations and developing vaccines.
China has improved its infection control measures in the aftermath of SARS, but common diseases still pose a problem.
The new company will develop, manufacture and commercialize treatments for chronic Hepatitis C virus infection in the Greater China region.
The Drugs for Neglected Diseases initiative has launched a clinical trial of a hepatitis C combination drug treatment which costs less than US$300.
Hepcvir-L will be provided to patients in India at the fraction of the cost of branded Ledipasvir-Sofosbuvir under a licensing agreement with Gilead Sciences Inc.